Thymus Cancer Market Research Report - Global Forecast till 2027

Thymus Cancer Market Research Report: Information by Cancer Type (Thymoma, Thymic Carcinoma), Treatment Type (Chemotherapy, Surgery, Radiation Therapy), End User (Hospitals & Clinics, Research & Academic Institutes) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2027

ID: MRFR/Pharma/1021-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill Sample form for updated data.

Market Scenario


Thymus Cancer Market is expected to register significant growth over the forecast period. The market was valued at approximately USD 481.85 Million in 2018 and is projected to register a 5.2% CAGR over the forecast period.


Thymus cancer occurs in a small organ that is located behind the sternum (breastbone) in front of the chest.


The rising prevalence of thymus cancer is expected to drive market growth. According to the National Cancer Institute (NCI), the incidence rate for thymoma is 0.15 cases per 100,000 people, as of 2016. Moreover, increasing research and development expenditure in the field of oncology for the development of innovative drugs to treat cancer is also expected to boost market growth.


However, the side effects of the treatment and stringent government regulations are expected to hamper the market growth. 


Thymus Cancer Market Segmentation

The Global Thymus Cancer Market has been segmented into Cancer Type, Treatment Type, End User, and Region.


Based on cancer type, the global thymus cancer market has been segmented into thymoma and thymic carcinoma.


The global thymus cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and others.


The global thymus cancer market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The thymus cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European thymus cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 


The thymus cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The Middle East & Africa thymus cancer market has been segmented into the Middle East and Africa.


Thymus Cancer Market Key Players


Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), Mylan NV (US), Johnson & Johnson Services, Inc. (US), Onxeo (France), Takeda Pharmaceutical Company Limited (Japan), Tiziana Life Sciences plc (UK), and Teva Pharmaceutical Industries Ltd (Israel) are some of the Key Players operating in the Global Thymus Cancer Market.


Regional Market Summary


Global Thymus Cancer Market Share (%), by Region, 2018  Thymus Cancer Market


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are expected to dominate the global thymus cancer market owing to the rising prevalence of thymus cancer. According to an article published by the American Society of Clinical Oncology in January 2019, in the US, approximately 400 people develop thymoma every year.


Europe is expected to hold the second-largest share of the thymus cancer market owing to the presence of major market players such as AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Onxeo, and Tiziana Life Sciences PLC.


Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing awareness regarding various types of cancer, including thymus cancer, the growing incidence rate of thymus cancer, and increasing R&D in the field of oncology. According to a report published by the National Center for Biotechnology Information (NCBI) in April 2016, the incidence rate of thymic tumors is approximately 3.93 per 1,000,000 people in China.


The thymus cancer market in the Middle East & Africa is expected to witness slow growth during the forecast period owing to the lack of awareness regarding the condition.


Global Thymus Cancer Market, by Cancer Type



  • Thymoma

  • Thymic Carcinoma


Global Thymus Cancer Market, by Treatment Type



  • Chemotherapy

  • Surgery

  • Radiation Therapy

  • Others


Global Thymus Cancer Market, by End User



  • Hospitals and Clinics

  • Research and Academic Institutes

  • Others


Global Thymus Cancer Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Biotechnology companies

  • Research institutes

  • Medical device companies

  • Pharmaceutical companies

  • Hospitals and clinics

  • Ambulatory surgical centers

  • Academic institutes

  • Government organizations



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 481.85 Million
  • 2027: Significant Value
  •   CAGR   5.2% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Cancer Type, Treatment Type and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), Mylan NV (US), Johnson & Johnson Services, Inc. (US), Onxeo (France), Takeda Pharmaceutical Company Limited (Japan), Tiziana Life Sciences plc (UK), and Teva Pharmaceutical Industries Ltd (Israel)
      Key Market Opportunities   side effects of the treatment and stringent government regulations
      Key Market Drivers

  • rising prevalence of thymus cancer
  • increasing research and development expenditure


  • Frequently Asked Questions (FAQ) :


    thymus cancer market is projected to grow at approximately 5.2% CAGR during the assessment period (2019-2025).

    The value of the global thymus cancer market had reached USD 481.85 MN in 2018.

    Increasing prevalence, availability of novel treatment options, and rising R&D expenditures in the field of oncology are major tailwinds pushing the growth of the global thymus cancer market.

    North America holds the largest share in the global thymus cancer market, followed by Europe and the Asia Pacific, respectively.

    Amgen Inc. (US), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), AstraZeneca (UK), Pfizer Inc. (US), Mylan NV (US), Onxeo (France), Johnson & Johnson Services, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), and Tiziana Life Sciences plc (UK), are some of the top players operating in the global thymus cancer market.